Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

Weak financing sentiment for Korean bioventures continues this year with sharply lower fund inflows from venture capital and other investors, as well as delayed or withdrawn IPOs, in Q2. Amyloid Solution, Rznomics, and UPPthera were among the top fundraisers.

German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.